Clinical Trial Update: To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to evaluate XNW5004 tablets in relapsed or refractory peripheral T-cell lymphoma has not yet begun recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• XNW5004

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING